In a separate study, Ogasawara et al. reported that, while the detection of PIK3CA and KRAS mutations in ctDNA was associated with advanced-stage disease, it did not correlate with histologic subtype or residual tumor burden [32], underscoring the need for further research to clarify the prognostic implications of ctDNA across different ovarian cancer subtypes. Here, KRAS is linked to neoplasm.